NCT02519439View on ClinicalTrials.gov

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

PHASE3TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Drug Resistant Partial Onset Seizure
Interventions
DRUG

ganaxolone

225 mg capsules 450 mg to 900 mg 2x/day

Trial Locations (5)

40504

Bluegrass Epilepsy Research, LLC, Lexington

55422

Minneapolis Clinic of Neurology, Golden Valley

75251

Texas Epilepsy Group, Dallas

90404

Neurological Research Institute, Santa Monica

07601

Northeast Regional Epilepsy Group, Hackensack

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT02519439 - A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures | Biotech Hunter | Biotech Hunter